Vimarsana
Biggest News Aggregation in the World

Page 7 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

Trutankless, Inc. Improves Balance Sheet - Vimarsana News

Trutankless, Inc. Improves Balance Sheet

Transforms Approximately $3 Million in Debt Conversions into Equity PHOENIX, April 9, 2024 /PRNewswire/ -- Trutankless, Inc. , the Company recently announced the launch of its new GEN3-series of...

Trutankless, Inc. Improves Balance Sheet - Vimarsana News

Trutankless, Inc. Improves Balance Sheet

Trutankless, Inc. , the Company recently announced the launch of its new GEN3-series of products with design upgrades to its flagship Trutankless products. Today, the Company announces the conversion of convertible debt-to-equity by investors....

Beyond Oil Announces Details for its Annual General & Special Meeting - Vimarsana News

Beyond Oil Announces Details for its Annual General & Special Meeting

Beyond Oil Announces Details for its Annual General & Special Meeting

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer - Vimarsana News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in...

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT - Vimarsana News

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...